drugset / Trial / NCT00031694

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

NCT00031694

Phase 2 Completed 19 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of combining paclitaxel and bryostatin-1 in treating patients who have locally advanced unresectable or metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bryostatin-1 may help paclitaxel kill more cancer cells by making tumor cells more sensitive to the drug.

Timeline

Start
2002-03
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 90 mg/m2 Intravenous
Subject bryostatin 1 Small molecule 25 ug/m2 Intravenous